AU2003291282B2 - N-oxides and derivatives of melphalan for treating diseased states associated with hypoxia inducible factor - Google Patents

N-oxides and derivatives of melphalan for treating diseased states associated with hypoxia inducible factor Download PDF

Info

Publication number
AU2003291282B2
AU2003291282B2 AU2003291282A AU2003291282A AU2003291282B2 AU 2003291282 B2 AU2003291282 B2 AU 2003291282B2 AU 2003291282 A AU2003291282 A AU 2003291282A AU 2003291282 A AU2003291282 A AU 2003291282A AU 2003291282 B2 AU2003291282 B2 AU 2003291282B2
Authority
AU
Australia
Prior art keywords
hif
cancer
compound
cells
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2003291282A
Other languages
English (en)
Other versions
AU2003291282A1 (en
Inventor
Lynn Kirkpatrick
Garth Powis
Sarah J. Welsh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Prolx Pharmaceuticals Corp
University of Arizona
Original Assignee
Prolx Pharmaceuticals Corp
University of Arizona
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prolx Pharmaceuticals Corp, University of Arizona filed Critical Prolx Pharmaceuticals Corp
Publication of AU2003291282A1 publication Critical patent/AU2003291282A1/en
Application granted granted Critical
Publication of AU2003291282B2 publication Critical patent/AU2003291282B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6581—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms
    • C07F9/6584—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms having one phosphorus atom as ring hetero atom
    • C07F9/65842—Cyclic amide derivatives of acids of phosphorus, in which one nitrogen atom belongs to the ring
    • C07F9/65846—Cyclic amide derivatives of acids of phosphorus, in which one nitrogen atom belongs to the ring the phosphorus atom being part of a six-membered ring which may be condensed with another ring system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2003291282A 2002-11-06 2003-11-03 N-oxides and derivatives of melphalan for treating diseased states associated with hypoxia inducible factor Ceased AU2003291282B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/288,888 2002-11-06
US10/288,888 US20040087556A1 (en) 2002-11-06 2002-11-06 N-oxides and derivatives of melphalan for treating diseased states associated with hypoxia inducible factor
PCT/US2003/035226 WO2004043359A2 (en) 2002-11-06 2003-11-03 N-oxides and derivatives of melphalan for treating diseased states associated with hypoxia inducible factor

Publications (2)

Publication Number Publication Date
AU2003291282A1 AU2003291282A1 (en) 2004-06-03
AU2003291282B2 true AU2003291282B2 (en) 2010-11-11

Family

ID=32175991

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003291282A Ceased AU2003291282B2 (en) 2002-11-06 2003-11-03 N-oxides and derivatives of melphalan for treating diseased states associated with hypoxia inducible factor

Country Status (7)

Country Link
US (2) US20040087556A1 (enExample)
EP (1) EP1567476A4 (enExample)
JP (1) JP2006508124A (enExample)
AU (1) AU2003291282B2 (enExample)
CA (1) CA2504496C (enExample)
MX (1) MXPA05004845A (enExample)
WO (1) WO2004043359A2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050049309A1 (en) * 2003-07-14 2005-03-03 Lynn Kirkpatrick Regulation of HIF protein levels via deubiquitination pathway
US20110092595A1 (en) * 2008-02-15 2011-04-21 Garth Powis Compositions and Methods for Treating Lung Cancer
WO2012058325A1 (en) * 2010-10-29 2012-05-03 Oncothyreon Inc. Compounds and methods useful for treatment of diseases mediated by hif-1
WO2012082765A2 (en) 2010-12-16 2012-06-21 The United State Of America. As Represented By The Secretary Department Of Health And Human Services Methods for decreasing body weight and treating diabetes
EP3102195B1 (en) 2014-02-03 2021-10-06 Quadriga Biosciences, Inc. Beta-substituted beta-amino acids and analogs as chemotherapeutic agents
EP3102194A1 (en) 2014-02-03 2016-12-14 Quadriga Biosciences, Inc. Beta-substituted gamma-amino acids and analogs as chemotherapeutic agents
US10349839B2 (en) * 2015-02-27 2019-07-16 Biotronik Se & Co. Implantable pressure sensor device
AR105592A1 (es) 2015-08-03 2017-10-18 Quadriga Biosciences Inc b-AMINOÁCIDOS b-SUSTITUIDOS Y ANÁLOGOS COMO AGENTES QUIMIOTERAPÉUTICOS Y USOS DE LOS MISMOS
US10842812B2 (en) 2015-08-12 2020-11-24 The General Hospital Corporation Compositions and methods that promote hypoxia or the hypoxia response for treatment and prevention of mitochondrial dysfunction and oxidative stress disorders
WO2018160772A1 (en) 2017-02-28 2018-09-07 The United State Of America, As Represented By The Secretary, Department Of Health & Human Services Method of treating obesity, insulin resistance, non-alcoholic fatty liver disease including non-alcoholic steatohepatitis
WO2020146758A1 (en) 2019-01-10 2020-07-16 The General Hospital Corporation Methods to treat mitochondrial-associated dysfunctions or diseases

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5602278A (en) * 1994-10-20 1997-02-11 Kirkpatrick; Lynn N-oxides and derivatives of chlorambucil for treating hypoxic tumor cells

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5602278A (en) * 1994-10-20 1997-02-11 Kirkpatrick; Lynn N-oxides and derivatives of chlorambucil for treating hypoxic tumor cells

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
M. TERCEL et al., J. Med. Chem., 1995, 38, 1247-1252 *
S. OWARI, Chem. Pharm. Bull., 1953, 1. 353-357 *
Y. SAKURAI et al., Chem. Pharm. Bull., 1953, 1. 297-301 *

Also Published As

Publication number Publication date
WO2004043359B1 (en) 2004-10-28
US7399785B2 (en) 2008-07-15
CA2504496A1 (en) 2004-05-27
AU2003291282A1 (en) 2004-06-03
EP1567476A2 (en) 2005-08-31
EP1567476A4 (en) 2008-09-24
JP2006508124A (ja) 2006-03-09
MXPA05004845A (es) 2005-10-05
CA2504496C (en) 2010-05-04
US20050026872A1 (en) 2005-02-03
WO2004043359A3 (en) 2004-09-10
WO2004043359A2 (en) 2004-05-27
US20040087556A1 (en) 2004-05-06

Similar Documents

Publication Publication Date Title
Li et al. Glutamine metabolism in cancer
Koh et al. Molecular mechanisms for the activity of PX-478, an antitumor inhibitor of the hypoxia-inducible factor-1α
Dowling et al. Metformin inhibits mammalian target of rapamycin–dependent translation initiation in breast cancer cells
CN101842095B (zh) 肿瘤治疗的配方,方法和靶目标
McCubrey et al. Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance
AU2021107577A4 (en) Flavagline derivatives for inhibition of kras oncogene activation
EP0831891B1 (en) Oxidant scavengers
CA2504496C (en) N-oxides and derivatives of melphalan for treating diseased states associated with hypoxia inducible factor
Kovacevic et al. The medicinal chemistry of novel iron chelators for the treatment of cancer
Han et al. A deep insight into ferroptosis in renal disease: facts and perspectives
US11090266B2 (en) Nanoliposomal c-MYC-siRNA inhibits in vivo tumor growth of cisplatin-resistant ovarian cancer
KR20220151027A (ko) Ｍｄｍ２ 억제제의 간헐적 투여
Wu et al. Ubiquitination regulates autophagy in cancer: simple modifications, promising targets
Ibrahim et al. Induction of the hypoxia-inducible factor system by low levels of heat shock protein 90 inhibitors
Deng et al. Mirk/dyrk1B kinase is upregulated following inhibition of mTOR
Bai et al. 5-(3, 4, 5-trimethoxybenzoyl)-4-methyl-2-(p-tolyl) imidazol (BZML) targets tubulin and DNA to induce anticancer activity and overcome multidrug resistance in colorectal cancer cells
US20220233535A1 (en) Use of inhibitors of yap/taz for the treatment of cancer
Oak et al. Curcumin mediates selective aggregation of mutant p53 in cancer cells: A promising therapeutic strategy
JP2009544679A (ja) 異常な細胞増殖に関連する疾患の治療におけるレチノイド及び小分子のＮｒｆ２アンタゴニストとしての使用
Matsuo et al. Preventing the unfolded protein response via aberrant activation of 4E‐binding protein 1 by versipelostatin
Masunaga et al. Usefulness of combined treatment with mild temperature hyperthermia and/or tirapazamine in the treatment of solid tumors: its independence of p53 status
Mao et al. DHODH-mediated suppression of ferroptosis supports radioresistance and represents a therapeutic vulnerability in lung cancer
WO2025198008A1 (ja) フェロトーシス誘導促進剤
US20050049309A1 (en) Regulation of HIF protein levels via deubiquitination pathway
JP2024501867A (ja) 肝細胞癌の処置、予防的治療、およびそれらの使用のための組成物

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired